Literature DB >> 18422730

Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection.

D Hegazy1, P Thurairajah, M Metzner, A Houldsworth, S Shaw, E Kaminski, A G Demaine, M E Cramp.   

Abstract

Cellular immunity with interferon gamma production could have a role in protection from hepatitis C virus (HCV). Interleukin (IL)-12 is a key cytokine in promoting such anti-viral T helper 1 (Th1) responses. We hypothesized that a genetic background able to promote cellular responses may be associated with apparent protection from infection and have investigated the distribution of the functional 1188A/C polymorphism of IL-12B in HCV exposed but uninfected cases. The frequency of the high IL-12-producing C allele was determined by restriction enzyme genotyping in 76 exposed-uninfected individuals and 105 healthy controls. Overall, the C allele was found in 27.6% of exposed-uninfected cases compared with 16.7% of healthy controls [chi(2) = 6.3, P = 0.02, odds ratio (OR) = 1.9, 95% confidence interval (CI) = 1.1-3.2]. CC genotype was found in 10.5% of exposed-uninfected cases compared with 0.9% controls (chi(2) = 9.3, P = 0.01, OR = 12, 95% CI = 1.5-100). Individuals at high risk of HCV infection yet who remain uninfected may be resistant in some way to infection. In our cohort of exposed-uninfected cases a genetic background of enhanced IL-12 production was associated with apparent resistance to HCV infection. This lends support to a central role for cellular immune responses in protecting from infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422730      PMCID: PMC2453209          DOI: 10.1111/j.1365-2249.2008.03655.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit.

Authors:  D Huang; M R Cancilla; G Morahan
Journal:  Genes Immun       Date:  2000-12       Impact factor: 2.676

2.  Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis.

Authors:  T van Veen; J B Crusius; H M Schrijver; G Bouma; J Killestein; L van Winsen; A Salvador Peña; C H Polman; B M Uitdehaag
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

3.  A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion.

Authors:  D Seegers; A Zwiers; W Strober; A S Peña; G Bouma
Journal:  Genes Immun       Date:  2002-11       Impact factor: 2.676

4.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

5.  Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research.

Authors:  M Thursz; R Yallop; R Goldin; C Trepo; H C Thomas
Journal:  Lancet       Date:  1999 Dec 18-25       Impact factor: 79.321

6.  Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele.

Authors:  G Morahan; D Huang; S I Ymer; M R Cancilla; K Stephen; P Dabadghao; G Werther; B D Tait; L C Harrison; P G Colman
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

7.  Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

Authors:  Matthew G Law; Gregory J Dore; Nicky Bath; Sandra Thompson; Nick Crofts; Kate Dolan; Wendy Giles; Paul Gow; John Kaldor; Stuart Loveday; Elizabeth Powell; Jenean Spencer; Alex Wodak
Journal:  Int J Epidemiol       Date:  2003-10       Impact factor: 7.196

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000.

Authors:  Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

10.  Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.

Authors:  Jeffrey J Post; Yong Pan; Anthony J Freeman; Charles E Harvey; Peter A White; Patricia Palladinetti; Paul S Haber; George Marinos; Michael H Levy; John M Kaldor; Kate A Dolan; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Infect Dis       Date:  2004-04-26       Impact factor: 5.226

View more
  6 in total

1.  Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Authors:  Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

2.  Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.

Authors:  Susanne Knapp; Usama Warshow; Doha Hegazy; Louise Brackenbury; I Neil Guha; Andrew Fowell; Ann-Margaret Little; Graeme J Alexander; William M C Rosenberg; Matthew E Cramp; Salim I Khakoo
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

3.  A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.

Authors:  Susanne Knapp; Usama Warshow; K M Alexander Ho; Doha Hegazy; Ann-Margaret Little; Andrew Fowell; Graeme Alexander; Mark Thursz; Matthew Cramp; Salim I Khakoo
Journal:  Gastroenterology       Date:  2011-04-14       Impact factor: 22.682

4.  Role of host genetic factors in the outcome of hepatitis C virus infection.

Authors:  Bertram Bengsch; Robert Thimme; Hubert E Blum
Journal:  Viruses       Date:  2009-08-05       Impact factor: 5.818

5.  Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.

Authors:  R E Swann; P Mandalou; M W Robinson; M M Ow; S K H Foung; J McLauchlan; A H Patel; M E Cramp
Journal:  J Viral Hepat       Date:  2016-07-13       Impact factor: 3.728

Review 6.  Uncovering Resistance to Hepatitis C Virus Infection: Scientific Contributions and Unanswered Questions in the Irish Anti-D Cohort.

Authors:  Jamie A Sugrue; Cliona O'Farrelly
Journal:  Pathogens       Date:  2022-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.